Literature DB >> 9506000

Atorvastatin does not alter the anticoagulant activity of warfarin.

R Stern1, R Abel, G L Gibson, J Besserer.   

Abstract

Twelve patients chronically maintained on warfarin were administered 80 mg atorvastatin for 2 weeks. Mean prothrombin times decreased slightly, but only for the first few days of the two-week treatment period. Thus atorvastatin had no consistent effect on the anticoagulant activity of warfarin and adjustment in warfarin dosing should not be necessary.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9506000     DOI： 10.1002/j.1552-4604.1997.tb04288.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


  9 in total

Review 1.  Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus.

Authors:  Katherine F Croom; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

Authors:  David Williams; John Feely
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects.

Authors:  Daisy Jindal; Monika Tandon; Sanjay Sharma; K K Pillai
Journal:  Eur J Clin Pharmacol       Date:  2005-10-19       Impact factor: 2.953

Review 4.  Drug interactions of lipid-altering drugs.

Authors:  H E Bays; C A Dujovne
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

5.  Use of statin therapy to reduce cardiovascular risk in older patients.

Authors:  N K Wenger; S J Lewis
Journal:  Curr Gerontol Geriatr Res       Date:  2010-06-08

6.  Safety of the combination of intensive cholesterol-lowering therapy with oral anticoagulation medication in elderly patients with atrial fibrillation: a randomized, double-blind, placebo-controlled study.

Authors:  Morteza Enajat; Steven Teerenstra; Janet T van Kuilenburg; Aty H N van Sorge-Greve; Marjo T H Albers-Akkers; Freek W A Verheugt; Gheorghe A M Pop
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

7.  Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk.

Authors:  Hedi Schelleman; Warren B Bilker; Colleen M Brensinger; Fei Wan; Yu-Xiao Yang; Sean Hennessy
Journal:  Am J Med       Date:  2010-02       Impact factor: 4.965

8.  Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.

Authors:  Toshiyuki Sakaeda; Hideki Fujino; Chiho Komoto; Mikio Kakumoto; Jiang-Shu Jin; Koichi Iwaki; Kohshi Nishiguchi; Tsutomu Nakamura; Noboru Okamura; Katsuhiko Okumura
Journal:  Pharm Res       Date:  2006-01-01       Impact factor: 4.580

9.  Analysis of potential interactions between warfarin and prescriptions in Estonian outpatients aged 50 years or more.

Authors:  Maia Gavronski; Sirpa Hartikainen; Alexander Zharkovsky
Journal:  Pharm Pract (Granada)       Date:  2012-03-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.